The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection

The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection

People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...

Bibliografski detalji
Glavni autor:	J. Karalliedde
Format:	Članak
Jezik:	Russian
Izdano:	«FIRMA «SILICEA» LLC 2021-04-01
Serija:	Российский кардиологический журнал
Teme:	cardiovascular disease hospitalization for heart failure end stage kidney disease
Online pristup:	https://russjcardiol.elpub.ru/jour/article/view/4323

Slični predmeti

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
od: John S. Clemmer, i dr.
Izdano: (2023-06-01)

Editorial: Recent advancement of the cardio-renal protective effects of SGLT2 inhibitors in people with and without diabetes
od: Satoru Kuriyama, i dr.
Izdano: (2023-10-01)

Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
od: Massimo Mapelli, i dr.
Izdano: (2023-06-01)

Assessment of Relationship between Galectin-3 and Biochemical Parameters in Peritoneal Dialysis Patients with Left Ventricular Hypertrophy
od: Sultan Alouffi, i dr.
Izdano: (2020-08-01)

Myocardial Cytoskeletal Adaptations in Advanced Kidney Disease
od: Arvin Halim, i dr.
Izdano: (2022-03-01)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
od: José C. De La Flor, i dr.
Izdano: (2023-07-01)

Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data
od: Christoph Wanner, i dr.
Izdano: (2025-01-01)

Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
od: Clipper F. Young, i dr.
Izdano: (2023-09-01)

Incidence of end‐stage renal disease after heart transplantation and effect of its treatment on survival
od: Stefan Roest, i dr.
Izdano: (2020-04-01)

Major cardiovascular events and associated factors among routine hemodialysis patients with end-stage renal disease at tertiary care hospital in Somalia
od: Mohamed Farah Yusuf Mohamud, i dr.
Izdano: (2023-05-01)

Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care dataResearch in context
od: Brendon L. Neuen, i dr.
Izdano: (2024-02-01)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
od: Carlo Garofalo, i dr.
Izdano: (2019-06-01)

ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION
od: F. I. Belyalov
Izdano: (2017-07-01)

SGLT2 inhibitors: Beyond glycemic control
od: Irtiza Hasan, i dr.
Izdano: (2024-03-01)

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
od: Jonathan C. H. Chan, i dr.
Izdano: (2023-02-01)

Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
od: Asmaa Elrakaybi, i dr.
Izdano: (2022-10-01)

Management of Cardiovascular Diseases in Chronic Hemodialysis Patients
od: Zhen Zhang, i dr.
Izdano: (2023-06-01)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
od: Sylvia Liu, i dr.
Izdano: (2024-06-01)

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
od: Hiroki Akiyama, i dr.
Izdano: (2023-01-01)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
od: Natalia G. Vallianou, i dr.
Izdano: (2021-06-01)

Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
od: André J. Scheen
Izdano: (2024-01-01)

SGLT2i: beyond the glucose-lowering effect
od: Lihua Ni, i dr.
Izdano: (2020-06-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
od: Angelica Cersosimo, i dr.
Izdano: (2024-10-01)

New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family
od: Abdellatif El Khayari, i dr.
Izdano: (2024-11-01)

Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease
od: Chi-Chih Hung, i dr.
Izdano: (2014-12-01)

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods
od: Hai‐Bin Chen, i dr.
Izdano: (2023-04-01)

Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD
od: Anand Srivastava, i dr.
Izdano: (2021-06-01)

Predictors of cardiovascular disease in peritoneal dialysis patients: A Prospective longitudinal cohort study
od: I. Shifris, i dr.
Izdano: (2022-11-01)

Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate
od: L. Di Lullo, i dr.
Izdano: (2017-03-01)

Impact of end stage renal disease on the clinical outcomes of diabetics admitted for heart failure: Analysis of national inpatient sample
od: Muhammad Usman Almani, i dr.
Izdano: (2023-03-01)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
od: Emily Brown, i dr.
Izdano: (2021-01-01)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
od: Liu, Sylvia, i dr.
Izdano: (2024)

Cardio-renal syndrome [version 1; referees: 3 approved]
od: Joseph Gnanaraj, i dr.
Izdano: (2016-08-01)

Editorial: CaRe Me: improving the cardio-renal-metabolic care of patients through clinical and translational research
od: José Jesús Broseta, i dr.
Izdano: (2024-07-01)

Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study
od: James B. Wetmore, i dr.
Izdano: (2019-08-01)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
od: Annalisa Capuano, i dr.
Izdano: (2022-11-01)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
od: Teruhiko Imamura, i dr.
Izdano: (2021-12-01)

A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i)
od: Sun H. Kim, i dr.
Izdano: (2020-07-01)

The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys
od: Eirini Lioudaki, i dr.
Izdano: (2022-03-01)

Retinopathy and Risk of Kidney Disease in Persons With DiabetesPlain-Language Summary
od: Jingyao Hong, i dr.
Izdano: (2021-09-01)